Key insights
- Personalis stock surged due to expanded Medicare coverage for its NeXT Personal MRD test, including immunotherapy monitoring. Deep Track Capital disclosed a 5.51% stake, and BTIG reiterated a Buy rating. This news builds on strong Q1 results, with NeXT Personal MRD test revenue growing significantly. The company reaffirmed its 2026 revenue guidance, anticipating substantial growth in biopharma MRD revenue. This positive company-specific news occurred despite a slightly negative broader market.
Investing.com -- Personalis stock surged +12.91% in morning trading, reaching $6.82, after the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program announced an expanded coverage decision for its NeXT Personal minimal residual disease test, extending reimbursement to include immunotherapy monitoring for patients with late-stage solid tumors. Analysts had noted that commercial teams were likely waiting on this exact CMS coverage decision for the immunotherapy monitoring test before scaling their sales activities. Because management had previously stated that 2026 guidance does not assume immunotherapy coverage, the announcement represented a meaningful upside surprise to investors.
Adding to the bullish momentum, Deep Track Capital and its affiliated entities disclosed beneficial ownership of 5,760,627 shares of Personalis common stock, representing a 5.51% stake, as of May 12, 2026. On the analyst front, BTIG maintained a Buy rating on Personalis, lowering its price target to $11 from $13 due to sector-wide multiple compression, while the coverage expansion news reinforces the bull case. The immunotherapy coverage news also builds directly on the company’s recent Q1 earnings momentum: Personalis delivered a first-quarter revenue beat and exceeded estimates for its NeXT Personal MRD test, which grew 258% year-over-year and 26% quarter-over-quarter, reaching over 1,000 oncologists ordering in the first quarter.
The broader market provided little tailwind for PSNL’s rally today. The S&P 500 was down 0.25%, the Dow Jones fell 0.41%, and the Nasdaq slipped 0.20%, meaning the stock’s sharp move was entirely driven by company-specific catalysts rather than macro sentiment. Personalis had reaffirmed its full-year 2026 revenue guidance of $78–80 million and anticipated significant growth in biopharma MRD revenue, expected to more than double year-over-year, providing a constructive fundamental backdrop heading into today’s news.
The combination of the expanded Medicare coverage decision — which opens a large new addressable patient population — alongside fresh institutional ownership disclosure and a strong Q1 earnings beat created a powerful convergence of catalysts. Personalis expects MRD biopharma clinical trials to build further in the second half of 2026 and is tracking to deliver approximately $20 million to $21 million of biopharma revenue this year, suggesting today’s coverage win could accelerate the company’s path toward margin recovery and commercial scale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.